tmem251 Antibody

What is TMEM251 and why is it important in cellular biology?

TMEM251 is a Golgi-localized transmembrane protein that plays a crucial role in the mannose-6-phosphate (M6P) biosynthetic pathway for lysosomal enzyme trafficking. It functions as a regulator of GlcNAc-1-phosphotransferase (GNPT), the enzyme responsible for adding M6P modifications to lysosomal enzymes . These M6P modifications serve as "postal codes" directing lysosomal enzymes to their proper destination. Without TMEM251, lysosomal enzymes lose their M6P modifications and are mistargeted for secretion rather than delivery to lysosomes, resulting in lysosomal dysfunction . The protein has been identified as having two transmembrane domains with both N and C termini facing the cytosol .

What are the main applications for TMEM251 antibodies in research?

TMEM251 antibodies are valuable tools for multiple experimental techniques including:

• Western blotting for protein expression and cleavage analysis

• Immunohistochemistry (IHC) for tissue localization studies

• Immunocytochemistry/Immunofluorescence (ICC/IF) for subcellular localization

• ELISA for quantitative protein detection

Most commercially available antibodies have been validated for human samples, with predicted cross-reactivity to mouse and rat homologs based on sequence conservation . When selecting an antibody, researchers should consider the specific epitope recognized, as some antibodies target the C-terminal region while others may recognize different domains of the protein .

How is TMEM251 localization typically visualized in cells?

TMEM251 primarily localizes to the Golgi apparatus, where it functions in the M6P pathway. For visualization:

• Use immunofluorescence with TMEM251 antibodies at dilutions of approximately 0.25-2 μg/ml

• Co-stain with established Golgi markers (e.g., GM130, TGN46) to confirm localization

• Fix cells with 4% paraformaldehyde to preserve membrane structures

• Permeabilize with 0.1-0.2% Triton X-100 to allow antibody access to intracellular antigens

Immunofluorescent staining of human cell lines like MCF7 shows TMEM251 localization primarily to the Golgi apparatus with some detection at cell junctions . When studying the relationship between TMEM251 and GNPT, co-staining experiments can reveal their co-localization at the Golgi .

How can researchers distinguish between the competing models of TMEM251 function in GNPT regulation?

Two competing models exist for TMEM251's role in GNPT regulation:

Model 1 (Processing Model): TMEM251 facilitates S1P-dependent cleavage and activation of GNPT .
Model 2 (Trafficking Model): TMEM251 anchors activated GNPT at the Golgi, preventing its mislocalization to lysosomes .

To experimentally distinguish between these models:

• Pulse-chase experiments: Track newly synthesized GNPTAB-V5 in wild-type and TMEM251 knockout cells. In one study, TMEM251 knockout resulted in both reduced cleavage and increased degradation of GNPTAB, supporting aspects of both models .

• S1P overexpression rescue: Determine if increased S1P levels can bypass TMEM251 dependence. While S1P overexpression partially rescued GNPT activity in TMEM251 knockout cells (increasing from 296 to 544 pmol/hr/mg protein), co-expression of TMEM251 with endogenous S1P had an even greater impact (3.4-fold increase) .

• Lysosome isolation: Assess GNPTαβ mislocalization to lysosomes in TMEM251 knockout cells. Researchers found GNPTαβ-3xHA was indeed mislocalized to lysosomes regardless of its cleavage state .

• BafA1 treatment: Inhibit lysosomal acidification and assess GNPT localization. Interestingly, BafA1 treatment stabilized GNPTαβ at the Golgi rather than the lysosome, suggesting complex regulation .

These experimental approaches collectively suggest TMEM251 plays multiple roles in GNPT regulation, including facilitating cleavage, maintaining stability, and preventing lysosomal mislocalization.

What are the optimal experimental conditions for studying TMEM251 and GNPT interactions?

To effectively study TMEM251-GNPT interactions:

• Cell models: HEK293T and SKMEL30 cell lines have been effectively used, with SKMEL30 showing higher endogenous expression of both TMEM251 and GNPTαβ .

• Protein tagging strategies:

  • For GNPTAB: C-terminal 3xHA tagging of endogenous protein using CRISPR/Cas9 knockin

  • For TMEM251: C-terminal GFP tagging that preserves normal function

• Co-immunoprecipitation conditions:

  • Mild detergents (0.5-1% NP-40 or 1% Digitonin) preserve protein-protein interactions

  • Cross-linking with DSP (dithiobis(succinimidyl propionate)) can stabilize transient interactions

• Functional assays:

  • GNPT enzymatic activity measurement (pmol/hr/mg protein)

  • M6P detection using single-chain antibody against M6P (scFv M6P)

  • Monitoring phosphorylated endogenous β-Hex levels as a downstream readout

When designing experiments to assess the functional relationship, expressing controlled amounts of TMEM251 (ranging from 50-400 ng cDNA) alongside a fixed amount of GNPTAB (400 ng) has demonstrated dose-dependent effects on GNPT cleavage and activity .

What disease models can be developed using TMEM251 knockout or mutation?

TMEM251 deficiency provides valuable models for studying:

• Lysosomal storage disorders: TMEM251 mutations cause a disease similar to mucolipidosis type II (MLII), characterized by skeletal dysplasia, coarsened facial features, short stature, and protruding abdomen with patients typically dying in childhood or early adulthood .

• Developmental models: In zebrafish, TMEM251 deletion leads to severe developmental defects including heart edema and skeletal dysplasia, phenocopying Mucolipidosis Type II .

• Cellular phenotyping:

  • Accumulation of undigested substrates in lysosomes

  • Hypersecretion of lysosomal enzymes

  • Defects in autophagy with SQSTM1/p62 and LC3B-II accumulation

For comprehensive disease modeling:

• Generate complete knockout models using CRISPR/Cas9

• Create patient-specific mutations for genotype-phenotype correlation studies

• Use conditional knockout systems (e.g., Cre-loxP) for tissue-specific effects

• Employ rescue experiments with wild-type or mutant TMEM251 to confirm causality

Some research groups have named this condition "Mucolipidosis Type V" to distinguish it from other mucolipidoses .

What are the best practices for using TMEM251 antibodies in immunohistochemistry?

For optimal immunohistochemistry results with TMEM251 antibodies:

• Tissue preparation and fixation:

  • Formalin-fixed paraffin-embedded (FFPE) tissues work well with most TMEM251 antibodies

  • Antigen retrieval using citrate buffer (pH 6.0) is typically recommended

• Antibody dilution ranges:

  • Most TMEM251 antibodies perform well at dilutions between 1:50 - 1:200 for IHC-P

  • Always perform titration experiments to determine optimal concentration

• Detection systems:

  • Polymer-based detection systems often provide better signal-to-noise ratio than avidin-biotin methods

  • DAB (3,3'-diaminobenzidine) is commonly used as the chromogen

• Tissue-specific considerations:

  • Human duodenum: Positive cytoplasmic staining in glandular cells

  • Human cerebellum: Positive cytoplasmic staining in granular layer cells

  • Human kidney: Positive cytoplasmic staining in tubule cells

  • Human prostate: Positive cytoplasmic and membranous staining

• Controls:

  • Include TMEM251 knockout tissues as negative controls

  • Use tissues known to express TMEM251 (e.g., kidney tubules) as positive controls

How can researchers troubleshoot inconsistent TMEM251 detection in immunoblotting?

When facing challenges with TMEM251 detection in Western blots:

• Sample preparation considerations:

  • TMEM251 is a relatively small protein (~18.7 kDa) but may appear at higher molecular weights due to post-translational modifications

  • Use fresh samples and avoid multiple freeze-thaw cycles

  • Include protease inhibitors in lysis buffers to prevent degradation

• Protein extraction optimization:

  • As a membrane protein, TMEM251 requires effective membrane solubilization

  • Try different detergents: RIPA buffer for standard extraction; 1% Triton X-100, NP-40, or digitonin for milder conditions

  • Consider specialized membrane protein extraction kits

• Gel electrophoresis parameters:

  • Use higher percentage gels (12-15%) for better resolution of TMEM251

  • Run gels at lower voltage (80-100V) for improved band sharpness

• Transfer and detection troubleshooting:

  • Ensure efficient transfer of small proteins by using 0.2μm PVDF membranes

  • Optimize transfer conditions: 250-300mA for 60-90 minutes or low voltage overnight transfer

  • Increase primary antibody incubation time (overnight at 4°C) for better sensitivity

• Signal enhancement strategies:

  • Use signal enhancers like Western Lightning Plus-ECL for chemiluminescent detection

  • Consider specialized detection systems for low-abundance proteins

When analyzing TMEM251 knockout samples, look for degradation products between 15-20 kDa that may appear with longer exposure times .

What experimental approaches can verify TMEM251 topology and membrane orientation?

Determining TMEM251's membrane topology is crucial for understanding its function. Current evidence indicates TMEM251 has two transmembrane domains with both N and C termini facing the cytosol . To verify this topology:

• Protease protection assays:

  • Perform selective permeabilization of plasma membrane with digitonin

  • Treat with proteinase K (30 μg/ml) for 1-2 minutes

  • Monitor GFP fluorescence quenching in TMEM251-GFP constructs

  • Include controls like Man1A1-GFP (Golgi lumenal protein, proteinase K resistant) and CTNS-GFP (lysosome membrane protein with cytosolic C-terminus, proteinase K sensitive)

• Glycosylation site mapping:

  • Introduce N-glycosylation sites at various positions in TMEM251

  • Only sites exposed to the ER lumen will be glycosylated

  • Assess glycosylation by mobility shift upon EndoH or PNGase F treatment

• Immunofluorescence with selective permeabilization:

  • Use antibodies targeting different domains of TMEM251

  • Compare staining patterns with or without membrane permeabilization

  • Domains accessible without permeabilization face the cytosol

• Cysteine accessibility method:

  • Introduce cysteine residues at various positions

  • Treat with membrane-impermeable sulfhydryl reagents

  • Determine accessibility by mass spectrometry

These methods collectively helped researchers determine that AlphaFold's prediction of three transmembrane helices was incorrect, and that TMEM251 actually possesses two transmembrane domains with a cytosol-facing orientation for both termini .

How should researchers interpret TMEM251 expression patterns across different tissues?

When analyzing TMEM251 expression patterns:

• Tissue-specific expression profiles:

  • TMEM251 shows widespread expression across multiple tissues

  • Immunohistochemical analysis reveals positive staining in:

    • Duodenum: Glandular cells (cytoplasmic)

    • Cerebellum: Granular layer cells (cytoplasmic)

    • Kidney: Tubule cells (cytoplasmic)

    • Prostate: Both cytoplasmic and membranous staining

• Subcellular localization considerations:

  • Primary localization is to the Golgi apparatus, consistent with its role in the M6P pathway

  • Some antibodies may detect additional localization at cell junctions

  • Staining patterns should be interpreted in context of co-stains with organelle markers

• Correlation with lysosomal biogenesis:

  • TMEM251 expression should be evaluated alongside markers of lysosomal function

  • Consider co-expression analysis with GNPTAB and other M6P pathway components

  • Tissues with high lysosomal activity may show enhanced TMEM251 expression

• Disease state interpretation:

  • Expression may be altered in lysosomal storage disorders

  • Evaluation in cancer samples may reveal connections to nutrient sensing, as research shows TMEM251 is critical for tumor propagation under nutrient-poor conditions

When comparing expression data across studies, account for differences in antibody specificity, detection methods, and tissue preparation protocols.

What controls are essential when validating TMEM251 knockdown or knockout models?

When generating and validating TMEM251 loss-of-function models:

• Genomic verification:

  • Sequence the targeted locus to confirm expected mutations

  • Verify absence of off-target effects through whole genome sequencing or targeted sequencing of predicted off-target sites

  • For knockdown models, use multiple siRNA/shRNA sequences to rule out off-target effects

• Expression validation:

  • Confirm protein depletion by Western blot with antibodies targeting different epitopes

  • Verify mRNA reduction through qPCR (studies show comparable levels of GNPTAB mRNA in TMEM251 knockout cells, indicating post-transcriptional effects)

  • Use immunofluorescence to confirm loss of TMEM251 signal

• Functional verification:

  • Assess M6P modification using scFv M6P antibody

  • Measure lysosomal enzyme secretion (increased in TMEM251 deficiency)

  • Evaluate lysosomal substrate accumulation

  • Monitor GNPT cleavage and activity (cleaved α and β subunits undetectable in TMEM251 knockout)

• Rescue experiments:

  • Re-expression of wild-type TMEM251 should restore normal phenotype

  • Use dose-dependent expression to establish quantitative relationships (studies show TMEM251 cDNA increasing ptase activity in a dose-dependent manner)

  • Test disease-associated mutants to confirm pathogenicity

• Cell type considerations:

  • Validate knockouts in multiple cell types (HEK293T and SKMEL30 have been successfully used)

  • Be aware that phenotype severity may vary between cell types

How can researchers reconcile contradictory findings about TMEM251 function in different experimental systems?

When faced with contradictory findings regarding TMEM251 function:

• Model system differences:

  • Different cell lines may show varying phenotypes due to expression levels of interacting proteins

  • HEK293T versus SKMEL30 cells show similar but not identical results regarding TMEM251 function

  • Consider species differences when comparing human, mouse, and zebrafish studies

• Methodological variations:

  • BafA1 treatment produces different outcomes across studies:

    • Some studies show BafA1 stabilizes GNPTαβ at the Golgi

    • Others report BafA1 stabilizes mislocalized GNPTαβ at the lysosome

  • Experimental timelines may capture different aspects of dynamic processes

• Integrative analysis approaches:

  • Combine multiple techniques to build comprehensive models

  • For example, pulse-chase experiments, S1P overexpression, lysosome isolation, and BafA1 treatment collectively suggest TMEM251 has multiple roles in GNPT regulation

  • Recent studies reconcile competing models by showing TMEM251 enhances GNPT cleavage AND prevents its mislocalization to lysosomes

• Unified model construction:

  • Develop comprehensive models that incorporate seemingly contradictory findings

  • Current evidence suggests TMEM251 functions at three distinct stages:

    1. Ensuring protein stability of GNPTαβ (regardless of cleavage state)

    2. Enhancing S1P cleavage efficiency during processing

    3. Maintaining enzymatic activity of cleaved GNPTαβ

• Precision in terminology:

  • Different names (TMEM251, LYSET, GCAF) reflect different proposed functions

  • Use consistent terminology and clearly define the aspect of function being studied

By carefully analyzing experimental conditions and integrating multiple lines of evidence, researchers can develop more complete models of TMEM251 function that reconcile apparently contradictory findings.

What are promising strategies for developing TMEM251-targeted therapeutics for lysosomal storage disorders?

Given TMEM251's critical role in lysosomal enzyme trafficking, several therapeutic strategies emerge:

• Gene therapy approaches:

  • AAV-mediated delivery of functional TMEM251 to affected tissues

  • CRISPR-based correction of patient-specific mutations

  • Design tissue-specific expression systems targeting most affected organs

• Small molecule screening:

  • Develop high-throughput assays monitoring GNPT cleavage and activity

  • Screen for compounds that:

    • Stabilize mutant TMEM251 proteins

    • Enhance GNPT-S1P interactions independently of TMEM251

    • Increase residual GNPT activity in disease states

• Alternative trafficking pathway exploitation:

  • Target M6P-independent lysosomal trafficking pathways to bypass TMEM251 deficiency

  • Modify lysosomal enzymes with alternative targeting signals

  • Explore sortilin-mediated or LIMP2-dependent trafficking mechanisms

• Enzyme replacement therapy optimization:

  • Current ERT for lysosomal storage disorders may be ineffective in TMEM251 deficiency

  • Develop modified recombinant enzymes with enhanced cellular uptake

  • Target specific tissues most affected by TMEM251 mutation

• Combination therapies:

  • Assess synergistic effects of substrate reduction therapy with partial restoration of TMEM251 function

  • Consider autophagy modulators to reduce substrate accumulation

The research showing that S1P overexpression can partially rescue GNPT activity in TMEM251 knockout cells suggests that enhancing S1P function could be a viable therapeutic approach .

How might TMEM251 research inform our understanding of other trafficking pathways beyond lysosomes?

TMEM251 research provides insights into broader cellular trafficking mechanisms:

• Golgi retention mechanisms:

  • TMEM251 interacts with GOLPH3 and retromer complexes to anchor the TMEM251-GNPT complex at the Golgi

  • The F4XXR7 motif in TMEM251's N-tail mediates GOLPH3 binding

  • This reveals principles of protein complex stabilization at the Golgi that may apply to other systems

• Proteolytic processing regulation:

  • TMEM251 enhances S1P-mediated cleavage of GNPT

  • This model could inform understanding of other S1P substrates like SREBP and ATF6

  • Suggests proteolytic activation may be regulated by accessory proteins more broadly

• Membrane protein topology determinants:

  • TMEM251's experimentally verified topology (two TMDs with cytosolic termini) contrasts with computational predictions

  • Highlights importance of experimental validation for membrane protein structure

  • May inform improved algorithms for topology prediction

• Recycling pathway interactions:

  • TMEM251's interaction with retromer suggests connections between anterograde and retrograde trafficking

  • Could provide insights into trafficking defects in neurodegenerative diseases where retromer function is compromised

• Organelle communication:

  • The relationship between Golgi retention and lysosomal mislocalization illustrates principles of inter-organelle communication

  • May inform understanding of contact sites and protein trafficking between compartments

What advanced imaging techniques can reveal new insights about TMEM251 dynamics and interactions?

Cutting-edge imaging approaches for TMEM251 research:

• Super-resolution microscopy:

  • Stimulated emission depletion (STED) microscopy can resolve TMEM251 distribution within Golgi subdomains

  • Single-molecule localization microscopy (STORM/PALM) can map TMEM251 nanoclusters and their relationship to GNPT

  • Expansion microscopy can physically enlarge samples to improve resolution of TMEM251-GNPT interactions

• Live-cell dynamics visualization:

  • FRAP (Fluorescence Recovery After Photobleaching) to measure TMEM251 mobility within membranes

  • Photoactivatable or photoconvertible TMEM251 fusions to track protein movement between compartments

  • Fast Airyscan or lattice light-sheet microscopy for rapid 3D imaging of trafficking events

• Protein-protein interaction imaging:

  • FRET (Förster Resonance Energy Transfer) sensors to visualize TMEM251-GNPT interactions in living cells

  • Split-fluorescent protein complementation assays for interaction validation

  • Proximity ligation assay (PLA) to detect endogenous protein interactions with high sensitivity

• Correlative microscopy approaches:

  • CLEM (Correlative Light and Electron Microscopy) to connect fluorescence patterns with ultrastructural context

  • FIB-SEM (Focused Ion Beam-Scanning Electron Microscopy) for 3D visualization of TMEM251-containing structures

  • Cryo-electron tomography of isolated Golgi membranes to visualize TMEM251-GNPT complexes in native state

• Label-free imaging technologies:

  • Mass spectrometry imaging to map tissue distribution without antibody limitations

  • Raman microscopy for chemical characterization of TMEM251-associated structures

  • Phase imaging for long-term monitoring of cellular responses to TMEM251 manipulation

These advanced imaging approaches, when combined with appropriate controls and quantitative analysis, can provide unprecedented insights into TMEM251's dynamic behavior and functional interactions in health and disease states.